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Table 1
Patient demographics
Characteristic Number/Median (range)
Number of patients 7
 Male 4
 Female 3
Age at diagnosis (years) 6.75 (1.3-12.5)
Telomere length <lst centile 7
Genetic Mutation
 TINF 2
 DKC1 1
 TERT 2
 RTEL1 1
 Unknown 1
Indication for HSCT
 Bone Marrow Failure 6
 MDS 1
Pre-HSCTs (in 4 patients)
 Mild decreased DLCO 1
 Mild restrictive disease 1
Table 2
Transplant characteristics
Characteristic Number/Median (range)
Age in years at HCT 7.12 (1.7-13.2)
Donor Source
 MSD 1
 URD 6
Donor HLA matching
 Full match 6
 One antigen mismatch 1
Cell dose - Median TNC ( 108/kg) 8.8 (5.5-10)
Neutrophil engraftment (days) 12 (10-16)
Platelet engraftment (days) 20 (14-35)
Mixed chimerism 0
GVHD
 Acute GVHD 2
-Skin Grade II 1
-Gut Grade III 1
 Chronic GVHD (limited) 1
Viral infection
 CMV 4
 EBV 3
 BK 3
 Adenovirus 1
Overall outcome
 Alive 5
 Dead 2
Cause of death (post HCT day of death)
 IPS 154
 MRSA sepsis 858
TNCeTotal Nucleated Cells, IPSeIdiopathic Pneumonia Syndrome, MRSA-
Methicillin-resistant Staphylococcus aureus.
Table 1
Total number of infections per age group
Age (years) 0-2 2-5 >5
n[78 n[58 n[170 p-value
GPC 16 18 44 0.38
GNR 21 7 31 0.09
Mold 1 0 5 0.54
Yeast 3 4 11 0.72
Viral 42 43 126 0.006
Adeno 12 21 37 0.02
BK 2 6 52 <0.0001
CMV 10 13 42 0.1
EBV 20 19 53 0.61
HHV6 4 7 11 0.25
Respiratory 16 9 41 0.38
Flu 4 0 6 0.27
Metapneumo 4 2 6 0.86
RSV 5 5 18 0.59
Paraﬂu 2 4 10 0.47
Rhino 6 4 11 0.95
Noro 7 5 13 0.88
Parvo 0 0 7 0.07
Rota 2 0 3 0.59
Other 0 0 1 1
GPC- gram positive cocci, GNR- gram negative rod, UTI- urinary tract
infection, CMV- cytomegalovirus, EBV- Epstein-Barr virus, HHV6- human
herpes virus 6, Flu- Inﬂuenza A or B, RSV- respiratory syncytial virus
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S234Background: HCT is the only curative option for progressive
marrow failure and/or myelosdysplastic syndrome or leu-
kemia associated with DC. HCT for DC is limited by a high
incidence of treatment-related mortality; related to under-
lying chromosomal instability resulting in sensitivity to
chemotherapy and radiation.We report our experience using
a reduced intensity conditioning (RIC) regimen without ra-
diation for HCT in patients with DC.
Methods: Retrospective chart review was performed with
IRB approval.
Results: 7 patients with DC underwent HSCT using a RIC
regimen consisting of alemtuzumab, ﬂudarabine, and lower
dose melphalan between September 2010 and April 2014.
Patient demographics and disease characteristics are shown
in Table 1.
1 patient with MDS and DC did not receive alemtuzumab
to avoid mixed chimerism. The remaining 6 patients all
received alemtuzumab at age appropriate dosing (on Day -22to -18, or day -14 to 10 or day -6 to -2). All patients received
ﬂudarabine fromdays -8 to -4 (30-40mg/m2/dose). Melphalan
dosewas reduced by 50% to 70mg/m2/dose, to avoid excessive
toxicity related to baseline chemo-sensitivity. GVHD prophy-
laxis consisted of cyclosporine and steroids or MMF. None of
the patients had pre-existing hepatic dysfunction.
All patients engrafted and none developed mixed
chimerism. See Table 2 for additional results. 2 patients
developed acute GVHD, one with grade 2 skin GVHD that
evolved in to limited chronic skin GVHD and the second
patient developed grade 3 gut GVHD in the setting of pre-
existing colitis.
5 patients remain alive and well (100% engrafted) at a
median follow up of 28 months (range 5-47.6).
Conclusion: A RIC regimen containing alemtuzumab, ﬂu-
darabine, and lower dose melphalan (without radiation) re-
sults in durable engraftment rates, acceptable toxicity and
improved overall survival inpatientswithDC undergoing HCT.317
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Background: Opportunistic infections signiﬁcantly
contribute to morbidity and mortality after HSCT. We hy-
pothesized that there is a difference in the infection rate
based on age at HSCT.
Methods: We retrospectively examined the medical records
of 307 pediatric allogeneic HSCT recipients between 2008
and 2012 at our institution to include all positive infectious
results (bacterial, viral and fungal). Screening practices were
consistent during the time period.
Table 2
Mean number of infections per patient.
Age 0-2 2-5 >5
n[79 n[58 n[170 p-value
GPC 0.37 0.59 0.36 0.27
GNR 0.35 0.12 0.3 0.23
Viral 0.72 1.28 1.34 0.0002
Adeno 0.15 0.38 0.25 0.03
BK 0.03 0.1 0.33 <0.0001
CMV 0.17 0.33 0.39 0.08
EBV 0.4 0.41 0.43 0.96
HHV6 0.06 0.14 0.07 0.3
Flu 0.06 0 0.04 0.19
Metapneumo 0.04 0.03 0.05 0.81
Noro 0.09 0.1 0.08 0.9
Paraﬂu 0.03 0.07 0.06 0.46
Parvo 0 0 0.05 0.06
Rhino 0.1 0.07 0.07 0.71
Rota 0.03 0 0.02 0.5
RSV 0.06 0.1 0.12 0.5
Other 0 0 0.01 0.67
GPC- gram positive cocci, GNR- gram negative rod, UTI- urinary tract
infection, CMV- cytomegalovirus, EBV- Epstein-Barr virus, HHV6- human
herpes virus 6, Flu- Inﬂuenza A or B, RSV- respiratory syncytial virus
Figure 1. The correlationbetween infectionsbefore transplantationandsurvival.
Figure 2. Results according to conditioning regimen.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S235Results: Patients were divided into age groups: 0-2yrs
(n¼79), 2-5yrs (n¼58) and>5yrs (n¼170). Table 1 shows the
number and type of infection per group. Viral infections
differed signiﬁcantly between the 0-2, 2-5 and >5 year age
groups (0.72, 1.28, 1.34, respectively) (Table 2). The
incidence of adenovirus and BK virus was lower amongst
those aged 0-2 years (0.15 and 0.03) compared to those
aged 2-5 years (0.38 and 0.1) and those aged >5 years
(0.25 and 0.33) respectively.
There was no difference in the rates of bacteremia or
fungal infections.
Conclusion: We demonstrate there is a signiﬁcantly lower
rate of viral infections in children <2yrs of age undergoing
allogeneic HSCT. It is surprising to note the reduced inci-
dence of adenovirus in children <2 years, though the dif-
ference in BK virusmay be explained by the natural history of
acquisition of the virus. The overall difference may be related
to their younger age at HSCT and low infectious burden
compared to other age groups. Careful monitoring and pro-
phylaxis for high risk individuals is necessary to further
reduce morbidity and mortality associated with infections in
this fragile population.
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SCID is a group of inherited diseases with genetic defects
characterized by severe abnormalities in the immune sys-
tem. The only potential cure is allogeneic hematopoietic
stem cell transplantation (SCT) and in rare cases gene
therapy.
Our objective herein was to review the outcome of factors
determining outcome of all children who received SCT for adiagnosis of SCID in Rambam Medical Center, Israel. From
1996 to 2013 twenty children with different genetic types of
SCID underwent SCT. Median age at SCT for 19 childrenwas 8
months; 1 child was transplanted at age of 14 years due to
loss of graft. Median time from diagnosis to SCT was 2
months.
11 children had graft from matched family donor, 6 from
sibling and 5 from other family members, 4-unrelated cord
and 5-Haploidentical SCT. Protocol regimen before SCT
included Busulphan-based in 50% of patients, 25% were
transplanted without conditioning regimen and 25% chil-
dren received Treosulphan based protocol. Overall survival
was 60%. Almost all survived children underwent SCT with
Busulphan conditioning regimen died from transplant
related complications. Most of the patients that were diag-
nosed late had severe infections before SCT. 6 children were
early diagnosed due to family history of SCID. They didn’t
suffer from any infections prior to transplantation and all
are alive (Figure 1). Better prognosis was also in a group
with Treosulphan based conditioning regimen (Figure 2).
Incidence of acute graft-versus host disease (GVHD)
was 15%.
Allogeneic SCT is effective for cure and survival in SCID pa-
tients. Early diagnosis of SCID and performing SCT before the
appearance of severe infection, as well as reduced toxicity
regimen will improve signiﬁcantly survival. Development of
new protocols with low toxicity drugs for Conditioning
regimen and newborn screening for SCID are needed for
highly favorable outcome.
